SCHEMBL4844477

SCHEMBL4844477

CCOC(=O)CCC[C@H]1CN(C(=O)OC(C)(C)C)CCN1C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
HPGD P15428 1/20 0.39
RECQL P46063 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PARP1 P09874 2/20 0.37
RAB9A P51151 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KAT7 O95251 1/20 0.37
NR1H2 P55055 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 1/20 0.36
FAAH O00519 1/20 0.35
TSHR P16473 1/20 0.35
CYP1A2 P05177 1/20 0.34
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4844498 0.93 PARP1 (0.36) ALDH1A1KDM4EGLAHPGDRECQL
SCHEMBL6730882 0.93 ALDH1A1 (0.40) ALDH1A1KDM4EGLAHPGDRECQL
SCHEMBL4843481 0.85 PARP1 (0.39) ALDH1A1HPGDHSD17B10PARP1KAT7
SCHEMBL21722174 0.85 PARP1 (0.39) ALDH1A1KDM4EGLAHPGDRECQL
SCHEMBL16846247 0.83 PARP1 (0.37) ALDH1A1KDM4EGLAHPGDRECQL
SCHEMBL29550830 0.82 ATM (0.44) ALDH1A1KDM4EGLAHPGDRECQL
SCHEMBL29550642 0.82 ATM (0.44) ALDH1A1KDM4EGLAHPGDRECQL
SCHEMBL4400854 0.82 ATM (0.44) ALDH1A1KDM4EGLAHPGDRECQL
SCHEMBL4836552 0.81 NR1H2 (0.43) ALDH1A1HPGDPARP1KAT7NR1H2
SCHEMBL5282029 0.81 FAAH (0.48) ALDH1A1KDM4EGLAHPGDRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384934-B2 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY (US) 2008-06-10 US disclosed
US-7384934-B2 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY (US) 2008-06-10 US disclosed
US-7384934-B2 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY (US) 2008-06-10 US disclosed
EP-1546134-B1 PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES LILLY CO ELI (US) 2007-05-02 EP disclosed
US-20060084643-A1 Piperazine substituted aryl benzodiazepines ELI LILLY AND COMPANY 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084643-A1 Piperazine substituted aryl benzodiazepines GABBR1, GABBR2, GABRA5 ALDH1A1 215/4885KDM4E 3606/4885GLA 3906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.